Cardiovascular risk and rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. - Université Paris Cité Accéder directement au contenu
Article Dans Une Revue Joint Bone Spine Année : 2006

Cardiovascular risk and rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion.

Arnaud Constantin
  • Fonction : Auteur
  • PersonId : 1119779
Stephan Pavy
  • Fonction : Auteur
Alain Cantagrel
  • Fonction : Auteur
  • PersonId : 918914
Xavier Mariette
Thierry Schaeverbeke

Résumé

OBJECTIVE: To develop clinical practice guidelines for the evaluation and management of cardiovascular risk in patients with rheumatoid arthritis (RA), using the evidence-based approach and expert opinion. METHODS: Recommendations were developed using the evidence-based approach and expert opinion: A scientific committee used a Delphi procedure to select five questions, which formed the basis for developing the recommendations; Evidence providing answers to the five questions was sought in the literature; Based on this evidence, recommendations were developed by a panel of experts. RESULTS: The recommendations were as follows: 1) In patients with RA, attention should be given to the risk of cardiovascular disease, which is responsible for an excess burden of morbidity and mortality; 2) It must be recognized that RA may be an independent cardiovascular risk factor. Persistent inflammation is an additional risk factor; 3) The cardiovascular risk should be evaluated, and modifiable risk factors should be corrected; 4) In patients with RA requiring glucocorticoid therapy, the need for cardiovascular risk minimization is among the reasons that mandate the use of the minimal effective dose; 5) It should be recognized that methotrexate may protect against cardiovascular mortality in patients with RA; 6) It should be recognized that TNFalpha antagonists remain contraindicated in patients with RA and severe heart failure. TNFalpha antagonists do not seem to worsen moderate heart failure and may protect against cardiovascular mortality; 7) AFSSAPS recommendations about LDL-cholesterol objectives should be followed, with active RA being counted as a cardiovascular risk factor; 8) In patients with RA, statin therapy should be considered only when cholesterol levels are elevated despite appropriate dietary treatment; 9) RA per se does not indicate aspirin for primary prevention. When aspirin is used for secondary prevention, it should be recognized that concomitant treatment with nonsteroidal antiinflammatory drugs (NSAIDs) may decrease the antiplatelet effects and increase the gastrointestinal side effects of aspirin therapy.

Dates et versions

hal-00465300 , version 1 (19-03-2010)

Identifiants

Citer

Thao Pham, Laure Gossec, Arnaud Constantin, Stephan Pavy, Eric Bruckert, et al.. Cardiovascular risk and rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion.. Joint Bone Spine, 2006, 73 (4), pp.379-87. ⟨10.1016/j.jbspin.2006.01.014⟩. ⟨hal-00465300⟩
325 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More